Absorption
Systems, a leader in testing drugs for ADMET
(Absorption, Distribution, Metabolism, Excretion and Toxicity), has
joined the Society of Toxicology, the premier global professional
association of toxicologists, as an SOT Affiliate. The firm, a contract
research organization, has more than a decade of experience assisting
pharmaceutical and biotechnology companies in determining which
compounds in development should be advanced into clinical testing.
Absorption Systems had focused on ADME testing for years, and broadened
its portfolio of services to include toxicology through the mid-2009
acquisition of an AAALAC-accredited GLP toxicology testing facility in
San Diego, CA.
“Absorption Systems is proud to become an affiliate of the Society of
Toxicology and will work to contribute to the organization’s continued
success”
Toxicologists may know Absorption Systems primarily as the company that
pioneered the Caco-2
cell model for in vitro prediction of oral drug absorption.
Today, the 100-person company offers a broad and deep service portfolio,
including in vitro, in situ and in vivo models to
assess the ADMET properties of small molecules. Additionally, Absorption
Systems provides in vivo testing of the safety and efficacy of
both small molecule drugs and biologics, medical devices, cardiovascular
and CNS pharmacology, diabetes, psoriasis and neutropenia.
“Absorption Systems is proud to become an affiliate of the Society of
Toxicology and will work to contribute to the organization’s continued
success,” said Dr. Sarath Kanekal, Absorption Systems’ Vice President of
Pharmacology and Toxicology and an SOT member for over 20 years.
“Absorption Systems has long been active in helping drug companies more
rapidly advance candidates to clinical testing. Now we have added
toxicology to that toolkit. We believe that by joining with others in
industry and research, we can make a greater impact in helping our
customers better appreciate the importance of conducting high-quality,
regulatory-driven toxicology studies.”
Research suggests no need for yellow fever vaccine booster after initial dose